NAN TANG^1,#, YAJING ZHAN^1,#, JIAYAN MAO^2,#, ANKANG YIN¹, WEI WANG^3,*, JUAN WANG^3,*

BIOCELL, Vol.47, No.9, pp. 2009-2026, 2023, DOI:10.32604/biocell.2023.029269 - 28 September 2023

Abstract Non-small cell lung cancer (NSCLC) is a malignant tumor with high incidence worldwide. Triptolide (TP), extracted from Tripterygium wilfordii Hook F, exhibits potent broad-spectrum antitumor activity. Although some mechanisms through which TP inhibits NSCLC are well understood, those that involve ribosomal proteins remain yet to be understood. In this study, the transcriptome and proteome were integrated and analyzed. Our data indicated ribosomal protein L4 (RPL4) to be a core hub protein in the protein-protein interaction network. RPL4 is overexpressed in NSCLC tissues and cells. Transfection with siRPL4 or TP treatment alone arrested the cell cycle in More > Graphic Abstract

Qin Liu^*†, Wei Wang^†, Fangqiong Li^†, Dongyang Yu^‡, Chunfen Xu^*, Hongbing Hu^*

Oncology Research, Vol.27, No.9, pp. 1043-1050, 2019, DOI:10.3727/096504019X15560124931900

Abstract Triptolide, an extract of Tripterygium wilfordii, has been shown to have a potent anticancer activity. In the present study, it was found that triptolide could effectively induce apoptosis and inhibit proliferation and invasion in malignant MDA-MB-231 breast cancer cells. The study focused on its effect on inhibiting invasion, which has not been extensively reported to date. We predicted that triptolide may change invasion activity via microRNAs (miRNAs), which have been recognized as important regulators of gene expression. miRNAome variation in MDA-MB-231 cells with or without triptolide treatment demonstrated that miR-146a was upregulated following treatment with triptolide.… More >

Jie Wei^*†1, Yuanliang Yan^*†1, Xi Chen^*†, Long Qian^*†, Shuangshuang Zeng^*†, Zhi Li^‡, Shuang Dai^*†, Zhicheng Gong^*†,Zhijie Xu^§

Oncology Research, Vol.27, No.7, pp. 849-858, 2019, DOI:10.3727/096504018X15447833065047

Abstract Over the past decade, natural compounds have been proven to be effective against many human diseases, including cancers. Triptolide (TPL), a diterpenoid triepoxide from the Chinese herb Tripterygium wilfordii Hook F, has exhibited attractive cytotoxic activity on several cancer cells. An increasing number of studies have emphasized the antitumor effects of TPL on non-small cell lung cancer (NSCLC). Here we mainly focused on the key molecular signaling pathways that lead to the inhibitory effects of TPL on human NSCLC, such as mitogen-activated protein kinases (MAPKs) modulation, inhibition of NF- B activation, suppression of miRNA expression, More >

Jian Jiang^*, Xuewen Song^†, Jing Yang^*, Ke Lei^*, Yongan Ni^*, Fei Zhou^‡, Lirong Sun^*

Oncology Research, Vol.26, No.8, pp. 1235-1243, 2018, DOI:10.3727/096504018X15179661552702

Abstract Neuroblastoma is the primary cause of cancer-related death for children 1 to 5 years of age. New therapeutic strategies and medicines are urgently needed. This study aimed to investigate the effects of triptolide (TPL), the major active component purified from Tripterygium wilfordii Hook F, on neuroblastoma SH-SY5Y cell proliferation, migration, and apoptosis, as well as underlying potential mechanisms. We found that TPL inhibited SH-SY5Y cell viability, proliferation, and migration, but induced cell apoptosis. The expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 after TPL treatment in SH-SY5Y cells was decreased. The expression of microRNA-181a (miR-181a) was upregulated More >